BioStock: Iconovo receives order for nasal Covid-19 vaccine development

Earlier this year, two Swedish life science companies, Iconovo, which develops complete inhalation products, and ISR, which develops immunotherapies, came together to start working on an inhalable Covid-19 vaccine using Iconovo’s ICOone platform. Now, the two companies have announced another agreement, this time for developing a nasal application of the vaccine using Iconovo’s new version of ICOone, called ICOone Nasal. The new application will lead to a faster track through clinical studies and thus a quicker path to market for this much-needed therapy.

Read the full article at biostock.se:

https://www.biostock.se/en/iconovo-receives-order-for-nasal-covid-19-vaccine-development/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se